hand, its use of ultrapure water and better biocompatibility profile make it a less inflammatory technique. Clinical studies have demonstrated a positive impact of these technical aspects in lowering B2-microglobulin amyloidosis, improving phosphate control and diminishing the rate of symptomatic hypotensive episodes, among others.
1. U S Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethseda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010.
2. EBPG Expert Group on Haemodialysis, Section IV. Dialysis fluid purity, Nephrol Dial Tranplant, 2002;17:45–62.
3. Canaud B, Mion CH, Water treatment for contemporary hemodialysis. In: Jacobs C, Kjellstradn CM, Koch KM, Winchester JF (eds), Replacement of Renal Function by Dialysis (4th edition), Dordrecht: Kluwer Academic Publishers, 1996;232–55.
4. Pedrini LA, De Cristofaro V, Pagliari B, et al., Mixed predilution and postdilution online hemodiafiltration compared with the traditional infusion modes, Kidney Int, 2000;58:2155–65.
5. Pedrini LA, De Cristofaro V, On-line mixed hemodiafiltration with a feedback for ultrafiltration control: Effect on middle-molecule removal, Kidney Int, 2003;64:1505–13.
6. Kim ST, Yamamoto C, Taoka M, et al., Programmed filtration, a new method for removing large molecules and regulating albumin leakage during hemodiafiltration treatment, Am J Kidney Dis, 2001;38(Suppl. 1):S220–3.
7. Krieter DH, Collins G, Summerton J, et al., Mid-dilution on-line haemodiafiltration in a standard dialyser configuration, Nephrol Dial Transplant, 2005;20:155–60.
8. Krieter DH, Falkenhain S, Chalabi L, et al., Clinical cross-over comparison of mid-dilution hemodiafiltration using a novel dialyzer concept and post-dilution hemodiafiltration, Kidney Int, 2005;67:349–56.
9. Miwa M, Shinzato T, Push/pull hemodiafiltration: technical aspects and clinical effectiveness, Artif Organs, 1999;23:1123–6.
10. Twardowski ZJ, PHD: the technical solution for daily haemodialysis?, Nephrol Dial Transplant, 2003;18:19–23.
11. Shinzato T, Miwa M, Nakai S, et al., Alternate repetition of short fore- and backfiltrations reduces convective albumin loss, Kidney Int, 1996;50:432–5.
12. Ing TS, Leong WH, Sam R, et al., Use of the adjective “membranous” to categorize hemodiafiltration and hemofiltration, Int J Artif Organs, 2006;29:815–7.
13. Ghezzi PM, Botella J, Sartoris AM, et al., Use of the ultrafiltrate obtained in two-chamber (PFD) hemodiafiltration as replacement fluid. Experimental ex vivo and in vitro study, Int J Artif Organs, 1991;14:327–34.
14. de Francisco Al, Pinera C, Heras M, et al., Hemodiafiltration with on-line endogenous reinfusion, Blood Purif, 2000;18:231–6.
15. Maduell F, Navarro V, Torregrosa E, et al., Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration, Kidney Int, 2003;64:305–13.
16. Vanholder R, Baurmeister U, Brunet P, et al., European Uremic Toxin Work Group. A bench to bedside view of uremic toxins, J Am Soc Nephrol, 2008;19:863–70.
17. Canaud B, Bosc JY, Leblanc M, et al., Evaluation of high-flux hemodiafiltration efficiency using an on-line urea monitor, Am J Kidney Dis, 1998;31:74–80.
18. Pedrini LA, De Cristofaro V, Comelli M, et al., Long-term effects of high-efficiency on-line haemodiafiltration on uraemic toxicity. A multicentre prospective randomized study, Nephrol Dial Transplant, 2011; [Epub ahead of print].
19. Shinzato T, Kobayakawa H, Maeda K, Comparison of various treatment modes in terms of beta 2-microglobulin removal: hemodialysis, hemofiltration, and push/pull HDF, Artif Organs, 1989;13:66–70.
20. Vanholder R, Meert N, Schepers E, Glorieux G, From uremic toxin retention to removal by convection: do we know enough?, Contrib Nephrol, 2008;161:125–31.
21. Santoro A, Ferramosca E, Mancini E, et al., Reverse mid- dilution:new way to remove small and middle molecules as well as phosphate with high intrafilter convective clearance, Nephrol Dial Transplant, 2007;22:2000–5.
22. Maduell F, Navarro V, Cruz MC, et al., Osteocalcin and myoglobin removal in on-line hemodiafiltration versus low- and high-flux hemodialysis, Am J Kidney Dis, 2002;40:582–9.
23. Zehnder C, Gutzwiller JP, Renggli K, Hemodiafiltration—A new treatment option for hyperphosphatemia in hemodialysis patients, Clin Nephrol, 1999;52:152–9.
24. Lornoy W, De Meester J, Because I ,et al., Impact of convective flow on phosphorus removal in maintenance hemodialysis patient, J Ren Nutr, 2006;16:47–53.
25. Penne EL, van der Weerd NC, van den Dorpel MA, et al., CONTRAST Inverstigators, Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST), Am J Kidney Dis, 2010;55:77–87.
26. Davenport A, Gardner C, Delaney M; on behalf of the Pan
Unfortunately, no firm conclusion can be drawn for the time being, relative to the hard end-point that constitutes mortality. Hopefully, ongoing randomized controlled trials comparing HDF with low- and/or high-flux hemodialysis (three of which have mortality as a primary end-point) should shed some light on this question in the near future.81–83
Thames Renal Audit Group, The effect of dialysis modality on phosphate control: haemodialysis compared to haemodiafiltration. The Pan Thames Renal Audit, Nephrol Dial Transplant, 2010;25:897–901.
27. Krieter DH, Lemke HD, Canaud B, Wanner C, Beta(2)- microglobulin removal by extracorporeal renal replacement therapies, Biochim Biophys Acta, 2005;1753:146–53.
28. Maduell F, el Pozo C, Garcia H, et al., Change from conventional haemodiafiltration to on-line haemodiafiltration, Nephrol Dial Transplant, 1999;14:1202.
29. Padrini R, Canova C, Conz P, et al., Convective and adsorptive removal of beta2-microglobulin during predilutional and postdilutional hemofiltration, Kidney Int, 2005;68:2331–7.
30. Susantitaphong P, Tiranathanagul K, Katavetin P, et al., Efficacy of convective-controlled double high-flux hemodiafiltration versus on-line hemodiafiltration: 1-year prospective study, Blood Purif, 2010;29:35–43.
31. Penne EL, van der Weerd NC, Blankestijn PJ, et al.; CONTRAST investigators, Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients, Clin J Am Soc Nephrol, 2010;5:80–6.
32. Locatelli F, Mastrangelo F, Redaelli B, et al., Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group, Kidney Int, 1996;50:1293.
33. Nakai S, Iseki K, Tabei K, et al., Outcomes of hemodiafiltration based on Japanese dialysis patient registry, Am J Kidney Dis, 2001;38(Suppl. 1):S212–6.
34. Sanders PW, Booker BB, Pathobiology of cast nephropathy from human Bence Jones proteins, J Clin Invest, 1992;89:630–9.
35. Huang ZQ, Kirk KA, Connelly KG, et al., Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation, J Clin Invest, 1993;92:2975–83.
36. Huang ZQ, Sanders PW, Biochemical interaction between Tamm- Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy, Lab Invest, 1995;73:810–7.
37. Granger Vallée A, Chenine L, Leray-Moragues H, et al., Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: Preliminary Quantitative Study, Nephrol Dial Transplant, 2011; [Epub ahead of print].
38. Meerwaldt R, Zeebregts CJ, Navis G, et al., Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis, Am J Kidney Dis, 2009;53:138–50.
39. Stein G, Franke S, Mahiout A, et al., Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients, Nephrol Dial Transplant, 2001;16:999.
40. Jourde-Chiche N, Dou L, Cerini C, et al., Protein-bound toxins: update 2009, Semin Dial, 2009;22:334–9.
41. Krieter DH, Hackl A, Rodriguez A, et al., Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration, Nephrol Dial Transplant, 2010;25:212–8.
42. Niwa T, Asada H, Tsutsui S, et al., Efficient removal of albumin- bound furancarboxylic acid by protein-leaking hemodialysis, Am J Nephrol, 1995;15:463–7.
43. Kawano Y, Takaue Y, Kuroda Y, et al., Effect on alleviation of renal anemia by hemodialysis using the high-flux dialyzer (BK-F), Kidney Dial, 1994;200–3.
44. Mion M, Kerr PG, Argiles A, et al., Haemodiafiltration in high-cardiovascular-risk patients, Nephrol Dial Transplant, 1992;7:453–4.
45. Locatelli F, Altieri P, Andrulli S, et al., Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD, J Am Soc Nephrol, 2010;21:1798–807.
46. van der Sande FM, Kooman JP, Konings CJ, Leunissen KM, Thermal effects and blood pressure response during postdilution hemodiafiltration and hemodialysis:the effect of amount of replacement fluid and dialysate temperature, J Am Soc Nephrol, 2001;12:1916–20.
47. Arese M, Cristol JP, Bosc JY, et al., Removal of constitutive and inducible nitric oxide synthase-active compounds in a modified hemodiafiltration with on-line production of substitution fluid: the contribution of convection and diffusion, Int J Artif Organs, 1996;19:704–11.
48. Hyodo T, Koutoku N, Preservation of residual renal function with HDF, Contrib Nephrol, 2011;168:204–12.
49. Stel VS, Dekker FW, Ansell D, et al., Residual renal function at the start of dialysis and clinical outcomes, Nephrol Dial Transplant, 2009;24:3175–82.
50. Penne EL, van der Weerd NC, Grooteman MP, et al.; CONTRAST investigators. Role of residual renal function in phosphate
control and anemia management in chronic hemodialysis patients, Clin J Am Soc Nephrol, 2011;6:281–9.
51. Panichi V, Rosati A, Bigazzi R, et al., Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study, Nephrol Dial Transplant, 2011; [Epub ahead of print].
52. Gil C, Lucas C, Possante C, et al., On-line hemodiafiltration decreases serum TNFalpha levels in hemodialysis patients, Nephrol Dial Transplant, 2003;18:447–8.
53. Carracedo J, Merino A, Nogueras S, et al. On-line hemodiafiltration reduces the proinflammatory CD14+CD16+ monocyte-derived dendritic cells: a prospective, crossover study, J Am Soc Nephrol, 2006;17:2315–21.
54. Panichi V, Manca-Rizza E, Paoletti S,et al., Effects on inflammatory and nutritional markers of haemodiafiltration with online regeneration of ultrafiltrate (HFR) vs online haemodialfiltration: a cross-over randomized multicentre trial, Nephrol Dial Transplant, 2006;21:756–62.
55. Stabellini G, Mariani G, Pezzetti F, Calastrini C, Direct inhibitory effect of uremic toxins and polyamines on proliferation of VERO culture cells, Exp Mol Pathol, 1997;64:147–55.
56. Yoshida K, Yoneda D, Kimura S, et al., Polyamines as an inhibitor on erythropoiesis of hemodialysis patients by in vitro bioassay using the fetal mouse liver assay, Ther Apher Dial, 2006;10:267–72.
57. Kushner D, Beckman B, Nguyen L, et al., Polyamines in the anemia of end-stage renal disease, Kidney Int, 1991;39:725–32.
58. Bonforte G, Grillo P, Zerbi S, Surian M, Improvement of anaemia in hemodialysis patients treated by hemodiafiltration with high volume on-line prepared substritution fluid, Blood Purif, 2002;20:357–63.
59. Lin CL, Huang CC, Yu CC, et al., Improved iron utilization and reduced erythropoietin resistance by on-line hemodiafiltration, Blood Purif, 2002;20:349–56.
60. Schiffl H, Prospective randomized cross-over long-term comparison of online haemodiafiltration and ultrapure high-flux haemodialysis, Eur J Med Res, 2007;12:26–33.
61. Vaslaki L, Major L, Berta K, et al., On-line hemodiafiltration versus hemodialysis: stable hematocrit with less erythropoietin and improvement of other relevant blood parameters, Blood Purif, 2006;24:163–73.
62. Wizemann V, Lotz C, Techert F, Uthoff S, On-line hemodiafiltration versus low-flux hemodialysis A prospective randomised study, Nephrol Dial Transplant, 2000;15(Suppl. 1):43–8.
63. Ward RA, Schmidt B, Hullin J, et al., A comparison of on-line hemodiafiltration versus high-flux hemodialysis. A prospective clinical study, J Am Soc Nephrol, 2000;11:2344–50.
64. Locatelli F, Manzoni C, Del Vecchio L, et al., Management of anemia by convective treatments, Contrib Nephrol, 2011;168:162–72.
65. Lindsay RM, Spanner E, Heidenheim AP, et al., A multicenter study of short hour dialysis using AN69S. Preliminary results, ASAIO Trans, 1991;37:M465–7.
66. Chazot C, [Can the hemodialysis strategy influence the nutritional status of hemodialysis patients?], Nephrol Ther, 2009;5(Suppl. 5):S330–3. [Article in French]
67. Fischbach M, Terzic J, Menouer S, et al., Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis, Nephrol Dial Transplant, 2010;25:867–73.
68. Locatelli F, Marcelli D, Conte F, et al., Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto, Kidney Int, 1999;55:286–93.
69. Bosch JP, Lew SQ, Barlee V, et al., Clinical use of high-efficiency hemodialysis treatments: long-term assessment, Hemodial Int, 2006;10:73–81.
70. Canaud B, Bragg-Gresham JL, Marshall MR, et al., Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS, Kidney Int, 2006;69:2087–93.
71. Jirka T, Cesare S, Di Benedetto A, et al., Mortality risk for patients receiving hemodiafiltration versus hemodialysis, Kidney Int, 2006;70:1524–5.
72. Vilar E, Fry AC, Wellsted D, et al., Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis, Clin J Am Soc Nephrol, 2009;4:1944–53.
73. Vinhas J, Vaz A, Barreto C, Assunção J, Survival advantage of patients on haemodiafiltration is independent of dialysis dose and patient characteristics: data from a single centre, Port J Nephrol Hypert, 2007;21:287–92.
74. Panichi V, Rizza GM, Paoletti S, et al., RISCAVID Study Group, Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study, Nephrol Dial Transplant, 2008;23:2337–43.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84